|Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial|
C Gridelli, F Perrone, C Gallo, S Cigolari, A Rossi, F Piantedosi, ...
Journal of the National Cancer Institute 95 (5), 362-372, 2003
|Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials|
Early Breast Cancer Trialists' Collaborative Group
The Lancet 386 (10001), 1341-1352, 2015
|Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer|
T Elderly Lung Cancer Vinorelbine Italian Study Group
Journal of the National Cancer Institute 91 (1), 66-72, 1999
|c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.|
C Carlomagno, F Perrone, C Gallo, M De Laurentiis, R Lauria, A Morabito, ...
Journal of Clinical Oncology 14 (10), 2702-2708, 1996
|Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy …|
P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ...
|Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data|
A Rossi, M Di Maio, P Chiodini, RM Rudd, H Okamoto, DV Skarlos, ...
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2012
|Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer|
N Normanno, M Di Maio, E De Maio, A De Luca, A De Matteis, A Giordano, ...
Endocrine-related cancer 12 (4), 721-747, 2005
|Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study|
G Colucci, R Labianca, F Di Costanzo, V Gebbia, G Cartenì, B Massidda, ...
Journal of Clinical Oncology 28 (10), 1645-1651, 2010
|Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial|
S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ...
The lancet oncology 15 (4), 396-405, 2014
|Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials|
M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ...
|Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non–small-cell lung cancer: A phase III trial of the Italian …|
C Gridelli, C Gallo, FA Shepherd, A Illiano, F Piantedosi, SF Robbiati, ...
Journal of clinical oncology 21 (16), 3025-3034, 2003
|Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions|
A Morabito, E De Maio, M Di Maio, N Normanno, F Perrone
The oncologist 11 (7), 753-764, 2006
|Treatment of advanced non–small-cell lung cancer in the elderly: Results of an international expert panel|
C Gridelli, M Aapro, A Ardizzoni, L Balducci, F De Marinis, K Kelly, ...
Journal of Clinical Oncology 23 (13), 3125-3137, 2005
|Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials|
M Di Maio, C Gridelli, C Gallo, F Shepherd, FV Piantedosi, S Cigolari, ...
The lancet oncology 6 (9), 669-677, 2005
|First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial|
C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ...
J Clin Oncol 30 (24), 3002-3011, 2012
|Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer|
M Di Maio, P Chiodini, V Georgoulias, D Hatzidaki, K Takeda, ...
J Clin Oncol 27 (11), 1836-1843, 2009
|The prognostic value of lymphatic and blood vessel invasion in operable breast cancer|
R Lauria, F Perrone, C Carlomagno, M De Laurentiis, A Morabito, C Gallo, ...
Cancer 76 (10), 1772-1778, 1995
|Lung cancer in the elderly|
C Gridelli, F Perrone, S Monfardini
European Journal of Cancer 33 (14), 2313-2314, 1997
|Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and …|
A Morabito, MC Piccirillo, F Falasconi, G De Feo, A Del Giudice, J Bryce, ...
The oncologist 14 (4), 378-390, 2009
|Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial|
S Pignata, G Scambia, G Ferrandina, A Savarese, R Sorio, E Breda, ...
Journal of clinical oncology 29 (27), 3628-3635, 2011